Abstract
Heart failure (HF) is a clinical syndrome defined by clinical symptoms and functional or structural cardiac abnormalities. Based on left ventricular ejection fraction, HF can be classified as reduced ejection fraction (HFrEF), mid-range ejection fraction (HFmrEF), or preserved ejection fraction (HFpEF). A hallmark feature of all of these forms of HF is reduced exercise capacity, measured as decreased peak exercise oxygen uptake (VO2peak). Every HFrEF and HFmrEF patient must be treated with optimal pharmacological therapy. Beside medical treatment, HF patients benefit from a healthy lifestyle which includes daily physical activity and a structured exercise training programme. Aerobic exercise training improves VO2peak and quality of life, and decreases hospitalization rates. The objective of this textbook chapter is to discuss the long-term benefits of exercise training and the optimal exercise prescription required to achieve these benefits in patients with HFrEF. In brief, an optimal exercise prescription includes exercising a minimum of 20 min each day at a moderate to high intensity, depending on their clinical status and exercise preferences. Exercise training should start with a short duration and low intensity during the first few weeks, which progressively increases over time while factoring patient tolerance and clinical status. HFrEF patients may also experience added benefits from the addition of resistance and respiratory training to basic aerobic training.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128(16):1810–52.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.
Association TCCotNYH. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Little & Brown; 1994.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.
Lip GY, Gibbs CR, Beevers DG. ABC of heart failure: aetiology. BMJ. 2000;320(7227):104–7.
Schindler MJ, Adams V, Halle M. Exercise in heart failure-what is the optimal dose to improve pathophysiology and exercise capacity? Curr Heart Fail Rep. 2019;16(4):98–107.
Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation. 2015;132(19):1786–94.
Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.
Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–91.
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–8.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA. 1995;273(18):1450–6.
Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.
The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA. 2000;283(10):1295–302.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.
O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439–50.
Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014;(4):CD003331.
Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2013;1(6):514–22.
Gomes Neto M, Duraes AR, Conceicao LSR, Saquetto MB, Ellingsen O, Carvalho VO. High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2018;261:134–41.
Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation. 2007;115(24):3086–94.
Ellingsen O, Halle M, Conraads V, Stoylen A, Dalen H, Delagardelle C, et al. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation. 2017;135(9):839–49.
Tucker WJ, Beaudry RI, Liang Y, Clark AM, Tomczak CR, Nelson MD, et al. Meta-analysis of exercise training on left ventricular ejection fraction in heart failure with reduced ejection fraction: a 10-year update. Prog Cardiovasc Dis. 2019;62(2):163–71.
Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, et al. Exercise training in heart failure: from theory to practice. A consensus document of the heart failure association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13(4):347–57.
Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, et al. AHA science advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, American Heart Association; position paper endorsed by the American College of Sports Medicine. Circulation. 2000;101(7):828–33.
Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory muscle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6(2):95–101.
Davids JS, McPherson CA, Earley C, Batsford WP, Lampert R. Benefits of cardiac rehabilitation in patients with implantable cardioverter-defibrillators: a patient survey. Arch Phys Med Rehabil. 2005;86(10):1924–8.
Dougherty CM, Glenny RW, Burr RL, Flo GL, Kudenchuk PJ. Prospective randomized trial of moderately strenuous aerobic exercise after an implantable cardioverter defibrillator. Circulation. 2015;131(21):1835–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Review
Review
1.1 Questions
-
1.
A 65-year old patient with newly diagnosed HF with reduced ejection fraction asks you for training recommendations. He was told by his doctor in hospital that regular exercise can improve fitness and HF symptoms. So instead of taking the pills, which were also recommended by the doctor he wants to start exercising. What’s your advice for the patient?
-
2.
The patient wants to know if he can start directly with the training program or if he has to do any additional testing. He was discharged from hospital 3 weeks ago and feels much better after being recompensated.
-
3.
After the examinations you discuss the results with the patient. There are no contraindications starting physical exercise. The VO2peak of 17 ml/kg/min shows a deconditioned physical status of the patient. The patient tells you that he has never done any sports in his life, but now he wants to start exercising to get fitter. A friend of him—also a HF patient—exercises every day a so called “high intensity training”. As a HIT takes less time than a moderate endurance training he would like to start tomorrow with that type of training. What’s your advice?
1.2 Answers
-
1.
A structured exercise program improves fitness, reduce HF symptoms and improves left ventricular function in patients with HFrEF. Even mortality may be reduced in the longer term. Therefore you confirm the beneficial effects of regular physical exercise in HFrEF patients. But physical activity is always a supportive therapy and should be performed in addition to the medical therapy only. The patient should definitely continue taking the recommended HF medication and should thereafter start a structured training program.
-
2.
As it is the first appointment of the patient in your clinic you will need medical information and perform medical examinations to rule out any contraindication for physical activity and to be able to give individual training recommendations. Beside medical history you will perform a clinical examination, an ECG and an echocardiography. In addition cardiopulmonary exercise testing will have to be performed by the patient in order to determine abnormalities under exercise as well as values of maximal exercise capacity for individual training recommendations.
-
3.
In general a moderate aerobic training as well as a high intensity training is possible for HFrEF patients when contraindication are excluded. But for the beginning of an exercise program HFrEF patients should always start with low or moderate intensity adapted to the individual fitness level. For very deconditioned patients—like your HFrEF patient—who has never done any kind of sports before, a daily activity of 5–10 min of low intensity is enough for the beginning. This amount of activity may also be done twice or even more frequently per day. In the next weeks first the duration of exercise should be increased, later the intensity. Overall a HIT is not recommended for the next weeks, but may be possible when physical performance increases over time without a deterioration of HF symptoms. For deconditioned patients a supervised setting is recommended.
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Heinicke, V., Tucker, W.J., Haykowsky, M.J., Halle, M. (2020). Exercise in Specific Diseases: Heart Failure with Reduced Ejection Fraction. In: Pressler, A., Niebauer, J. (eds) Textbook of Sports and Exercise Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-35374-2_46
Download citation
DOI: https://doi.org/10.1007/978-3-030-35374-2_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35373-5
Online ISBN: 978-3-030-35374-2
eBook Packages: MedicineMedicine (R0)